Literature DB >> 18721770

HLAMatchmaker-defined triplet matching is not associated with better survival rates of patients with class I HLA allele mismatched hematopoietic cell transplants from unrelated donors.

Rene Duquesnoy1, Stephen Spellman2, Michael Haagenson3, Tao Wang4, Mary M Horowitz4, Machteld Oudshoorn5.   

Abstract

This report addresses the concept that permissible HLA mismatching, that is, mismatches that do not generate an allogeneic response, in hematopoietic stem cell transplantation (HCT) can be determined with structural similarity of polymorphic regions. We have applied the triplet version of a structural algorithm called HLAMatchmaker, which considers short sequences involving polymorphic amino acid residues on the molecular surface as key elements of immunogenic epitopes. The triplet matching effect was analyzed in a National Marrow Donor Program dataset consisting of 744 unrelated hematopoietic cell transplantation cases with 1 HLA-A, -B, or -C mismatch and 1690 fully HLA-A, -B, -C, -DR, or -DQ allele matched cases. In multivariate models adjusting for other significant clinical risk factors, the degree of triplet mismatching did not significantly correlate with patient survival, engraftment, or acute graft-versus-host disease (aGVHD). Other structurally based strategies should be pursued to identify permissible HLA mismatches in HCT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18721770      PMCID: PMC2572684          DOI: 10.1016/j.bbmt.2008.07.001

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  40 in total

Review 1.  Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism.

Authors:  A Sette; J Sidney
Journal:  Immunogenetics       Date:  1999-11       Impact factor: 2.846

2.  Sequence similarity matching: proposal of a structure-based rating system for bone marrow transplantation.

Authors:  H-A Elsner; R Blasczyk
Journal:  Eur J Immunogenet       Date:  2002-06

3.  Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation.

Authors:  E W Petersdorf; J A Hansen; P J Martin; A Woolfrey; M Malkki; T Gooley; B Storer; E Mickelson; A Smith; C Anasetti
Journal:  N Engl J Med       Date:  2001-12-20       Impact factor: 91.245

4.  Cytotoxic T lymphocytes recognize a reconstituted class I histocompatibility antigen (HLA-A2) as an allogeneic target molecule.

Authors:  T J Elliott; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

5.  Relevance of KIR gene polymorphisms in bone marrow transplantation outcome.

Authors:  Katia Gagne; Géraldine Brizard; Brigitte Gueglio; Noël Milpied; Patricia Herry; Françoise Bonneville; Mary Luce Chéneau; Nicolas Schleinitz; Anne Cesbron; Gilles Folléa; Jean Luc Harrousseau; Jean Denis Bignon
Journal:  Hum Immunol       Date:  2002-04       Impact factor: 2.850

6.  Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain.

Authors:  G B Ferrara; A Bacigalupo; T Lamparelli; E Lanino; L Delfino; A Morabito; A M Parodi; C Pera; S Pozzi; M P Sormani; P Bruzzi; D Bordo; M Bolognesi; G Bandini; A Bontadini; M Barbanti; G Frumento
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

7.  HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm.

Authors:  René J Duquesnoy
Journal:  Hum Immunol       Date:  2002-05       Impact factor: 2.850

8.  HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. II. Verification of the algorithm and determination of the relative immunogenicity of amino acid triplet-defined epitopes.

Authors:  René J Duquesnoy; Marilyn Marrari
Journal:  Hum Immunol       Date:  2002-05       Impact factor: 2.850

9.  Genetic control of human NK cell repertoire.

Authors:  Heather G Shilling; Neil Young; Lisbeth A Guethlein; Nathalie W Cheng; Clair M Gardiner; Dolly Tyan; Peter Parham
Journal:  J Immunol       Date:  2002-07-01       Impact factor: 5.422

10.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Authors:  Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

View more
  18 in total

1.  Donor registries and search strategies.

Authors:  Carolyn K Hurley; Machteld Oudshoorn; Michelle Setterholm
Journal:  Methods Mol Biol       Date:  2012

2.  A perspective on the selection of unrelated donors and cord blood units for transplantation.

Authors:  Stephen R Spellman; Mary Eapen; Brent R Logan; Carlheinz Mueller; Pablo Rubinstein; Michelle I Setterholm; Ann E Woolfrey; Mary M Horowitz; Dennis L Confer; Carolyn K Hurley
Journal:  Blood       Date:  2012-05-17       Impact factor: 22.113

3.  HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment.

Authors:  Joseph Rimando; Michael Slade; John F DiPersio; Peter Westervelt; Feng Gao; Chang Liu; Rizwan Romee
Journal:  Blood Adv       Date:  2018-12-26

4.  Matching inside and outside the HLA molecule in allogeneic hematopoietic stem cell transplantation.

Authors:  J Alejandro Madrigal; Linda D Barber
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

5.  Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation.

Authors:  Marcelo A Fernandez-Viña; Tao Wang; Stephanie J Lee; Michael Haagenson; Mahmoud Aljurf; Medhat Askar; Minoo Battiwalla; Lee-Ann Baxter-Lowe; James Gajewski; Ann A Jakubowski; Susana Marino; Machteld Oudshoorn; Steven G E Marsh; Effie W Petersdorf; Kirk Schultz; E Victoria Turner; Edmund K Waller; Ann Woolfrey; John Umejiego; Stephen R Spellman; Michelle Setterholm
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

6.  Scoring HLA class I mismatches by HistoCheck does not predict clinical outcome in unrelated hematopoietic stem cell transplantation.

Authors:  Stephen Spellman; John Klein; Michael Haagenson; Medhat Askar; Lee Ann Baxter-Lowe; Jun He; Susan Hsu; Rainer Blasczyk; Carolyn Hurley
Journal:  Biol Blood Marrow Transplant       Date:  2011-09-29       Impact factor: 5.742

7.  HLA-A disparities illustrate challenges for ranking the impact of HLA mismatches on bone marrow transplant outcomes in the United States.

Authors:  Lee Ann Baxter-Lowe; Martin Maiers; Stephen R Spellman; Michael D Haagenson; Tao Wang; Marcelo Fernandez-Vina; Steven G E Marsh; Mary Horowitz; Carolyn Katovich Hurley
Journal:  Biol Blood Marrow Transplant       Date:  2009-08       Impact factor: 5.742

8.  In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance.

Authors:  Esteban Arrieta-Bolaños; Pietro Crivello; Bronwen E Shaw; Kwang Woo Ahn; Hai-Lin Wang; Michael R Verneris; Katharine C Hsu; Joseph Pidala; Stephanie J Lee; Katharina Fleischhauer; Stephen R Spellman
Journal:  Blood Adv       Date:  2018-07-24

9.  Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task.

Authors:  S R Marino; S M Lee; T A Binkowski; T Wang; M Haagenson; H-L Wang; M Maiers; S Spellman; K van Besien; S J Lee; T Karrison; A Artz
Journal:  Bone Marrow Transplant       Date:  2016-05-23       Impact factor: 5.483

10.  HLA mismatches and hematopoietic cell transplantation: structural simulations assess the impact of changes in peptide binding specificity on transplant outcome.

Authors:  Chen Yanover; Effie W Petersdorf; Mari Malkki; Ted Gooley; Stephen Spellman; Andrea Velardi; Peter Bardy; Alejandro Madrigal; Jean-Denis Bignon; Philip Bradley
Journal:  Immunome Res       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.